Trial Profile
A Retrospective study to evaluate the influence of gender on onabotulinum toxin A dose in patients with adductor spasmodic dysphonia
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 May 2017
Price :
$35
*
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Dysphonia
- Focus Therapeutic Use
- 23 May 2017 New trial record
- 01 May 2017 Results published in the Laryngoscope